Amneal Pharmaceuticals, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $862.7 million (+10.0% year over year) and diluted EPS of -$0.06. It usually reports 13–34 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 12, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Jan 13, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 13–34 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
863
+10.0%
|
—
|
-0.06
-700.0%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
796
+9.9%
|
58
+157.2%
|
0.18
+157.1%
|
|
Apr 22, 2026
22 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
723
+3.9%
|
62
+410.5%
|
0.19
+375.0%
|
|
Jan 13, 2026
13 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
814
+11.5%
|
35
|
0.11
+206.6%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
785
+11.7%
|
2
+1618.6%
|
0.01
|
|
Jul 21, 2025
21 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
725
+3.2%
|
22
+274.0%
|
0.07
+250.0%
|
|
May 2, 2025
32 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
695
+5.5%
|
12
+113.3%
|
0.04
+113.3%
|
|
Jan 15, 2025
15 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
731
+18.4%
|
—
|
-0.10
+76.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRX (Nasdaq)
- Fiscal year ends
- December 31
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1723128
- Former names
- Atlas Holdings, Inc. (until Apr 13, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.